STERIS (STE) 10-Q 7 Aug 19 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	3 Months Ended
	Jun. 30, 2019	Aug. 02, 2019
Entity Information [Line Items]
Document Transition Report	false
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Entity Incorporation, State or Country Code	L2
Document Quarterly Report	true
Entity Registrant Name	STERIS plc
Local Phone Number	1 232 2000
Entity Central Index Key	0001757898
Document Type	10-Q
Entity File Number	001-38848
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		84,686,637
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Tax Identification Number	98-1455064
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, State or Province	IE
Entity Address, Postal Zip Code	D02 R296
Trading Symbol	STE
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	353

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Current assets:
Cash and cash equivalents	$ 238,067	$ 220,633
Accounts receivable (net of allowances of $10,606 and $9,645 respectively)	509,655	564,830
Inventories, net	233,587	208,243
Prepaid expenses and other current assets	62,973	60,029
Total current assets	1,044,282	1,053,735
Property, plant, and equipment, net	1,054,217	1,031,582
Operating Lease, Right-of-Use Asset	122,521	0
Goodwill	2,347,329	2,322,928
Intangible Assets, Net (Excluding Goodwill)	602,179	604,614
Other assets	59,195	60,212
Total assets	5,229,723	5,073,071
Current liabilities:
Accounts payable	135,487	152,913
Accrued income taxes	25,041	15,460
Accrued payroll and other related liabilities	69,303	109,058
Capital Lease Obligations, Current	20,139	0
Accrued expenses and other	182,804	187,765
Total current liabilities	432,774	465,196
Long-term indebtedness	1,210,003	1,183,227
Deferred income taxes, net	154,385	151,038
Capital Lease Obligations, Noncurrent	102,488	0
Other Liabilities, Noncurrent	85,071	87,812
Total liabilities	1,984,721	1,887,273
Commitments and contingencies (see Note 8)
Common shares, with $.001 and $75 par value; 500,000 shares authorized; 84,754 and 84,517 shares issued and outstanding	1,996,354	1,998,564
Retained earnings	1,397,390	1,339,024
Accumulated other comprehensive income	(156,844)	(159,778)
Total shareholders' equity	3,236,900	3,177,810
Noncontrolling interest	8,102	7,988
Total equity	3,245,002	3,185,798
Total liabilities and equity	$ 5,229,723	$ 5,073,071

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Accounts Receivable, Allowance for Credit Loss, Current	$ 10,606	$ 9,645
Preferred Stock, Shares Authorized	50,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Common Stock, Shares Authorized	$ 500,000	$ 500,000
Common Stock, Shares, Issued	500,000,000	500,000,000
Common Stock, Shares, Outstanding	84,754,000	84,517,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 75
Intangible Assets, Net (Excluding Goodwill)	$ 602,179	$ 604,614

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Revenues:
Total revenues	$ 696,803	$ 638,758
Cost of revenues:
Total cost of revenues	390,960	369,708
Gross Profit	305,843	269,050
Operating expenses:
Selling, general, and administrative	178,781	158,406
Research and development	15,585	16,220
Restructuring Costs	1,389	0
Total operating expenses	195,755	174,626
Income from operations	110,088	94,424
Non-operating expenses, net:
Interest expense	10,445	11,740
Interest income and miscellaneous expense	233	(367)
Total non-operating expenses, net	10,678	11,373
Income before income tax expense	99,410	83,051
Income tax expense	14,633	12,773
Net Income	84,777	70,278
Less: Net Income Attributable to Noncontrolling Interest	187	287
Net income (loss) attributable to shareholders	$ 84,590	$ 69,991
Net income per common share [Abstract]
Basic	$ 1	$ 0.83
Diluted	0.99	0.82
Cash dividends declared per common share outstanding	$ 0.34	$ 0.31
Product [Member]
Revenues:
Total revenues	$ 307,735	$ 278,790
Cost of revenues:
Cost of Goods and Services Sold	160,959	146,602
Service [Member]
Revenues:
Total revenues	389,068	359,968
Cost of revenues:
Cost of Goods and Services Sold	$ 230,001	$ 223,106

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Net Income	$ 84,777	$ 70,278
Less: Net Income Attributable to Noncontrolling Interest	187	287
Net income (loss) attributable to shareholders	84,590	69,991
Other comprehensive (loss) income
Amortization of pension and postretirement benefits plans costs, (net of taxes of $170 and $169, respectively)	(505)	(410)
Change in cumulative foreign current translation adjustment	3,439	(130,401)
Total other comprehensive (loss) income	2,934	(130,811)
Comprehensive income	87,524	(60,820)
Other comprehensive (loss) income (parenthetical)
Amortization of pension and postretirement benefits plans costs, tax	$ 170	$ 169

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2019	Jun. 30, 2018
Net Income		$ 84,777	$ 70,278
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, depletion, and amortization		47,102	46,854
Deferred income taxes		(612)	225
Share-based compensation		5,537	5,237
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net		61	(568)
Loss on sale of businesses, net	[1]	2,426	444
Other items		596	(21,081)
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net		57,620	39,225
Inventories, net		(24,622)	(34,063)
Other current assets		(2,480)	(2,424)
Accounts payable		(17,276)	(1,883)
Accruals and other, net		(43,792)	(1,465)
Net cash provided by operating activities		109,337	100,779
Investing activities:
Purchases of property, plant, equipment, and intangibles, net		(49,794)	(27,726)
Proceeds from the sale of property, plant, equipment, and intangibles		18	2,795
Proceeds from Divestiture of Businesses, Net of Cash Divested		439	(196)
Purchase of investments		0	(4,955)
Acquisition of businesses, net of cash acquired		(34,970)	0
Payments for (Proceeds from) Other Investing Activities		0	(4,784)
Net cash used in investing activities		(84,307)	(34,866)
Financing activities:
Proceeds (Payments) under credit facilities, net		27,861	18,443
Deferred financing fees and debt issuance costs		(1,206)	(298)
Acquisition related deferred or contingent consideration		(452)	(685)
Repurchases of ordinary shares		(14,886)	(33,844)
Cash dividends paid to ordinary shareholders		(28,823)	(26,265)
Stock option and other equity transactions, net		9,899	3,435
Net cash used in financing activities		(7,607)	(39,214)
Effect of exchange rate changes on cash and cash equivalents		11	(9,709)
Increase (decrease) in cash and cash equivalents		17,434	16,990
Cash and cash equivalents at beginning of period		220,633	201,534
Cash and cash equivalents at end of period		$ 238,067	$ 218,524
[1]	For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2019 , dated May 30, 2019 .

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	AOCI Attributable to Noncontrolling Interest [Member]	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Common Stock [Member]
Shares, Issued						84,747
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,217,300		$ 11,340	$ 11,685	$ 1,146,223	$ 2,048,037
Preferred Stock, Shares Outstanding	100
Preferred Stock, Value, issued	$ 15
Common Stock, Dividends, Per Share, Cash Paid	$ 0.31
Net Income (Loss) Attributable to Parent	$ 69,991			0	69,991	$ 0
Net Income (Loss) Attributable to Noncontrolling Interest	287		287
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	70,278
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(130,811)			(130,811)
Treasury Stock, Shares, Acquired						(349)
Payments for Repurchase of Common Stock	(33,844)			0	(4,765)	$ (29,079)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture						253
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	8,046		0	0	0	$ 8,046
Dividends, Common Stock, Cash	(26,265)		0	0	(26,265)	0
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	(5,637)	$ (1,970)			(3,667)
Noncontrolling Interest, Change in Redemption Value	121		121	0	0	$ 0
Shares, Issued						84,651
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,099,188
Preferred Stock, Shares Outstanding	100
Preferred Stock, Value, issued	$ 15
Stockholders' Equity Attributable to Parent				(121,096)	1,181,517	$ 2,027,004
Stockholders' Equity Attributable to Noncontrolling Interest			11,748
Shares, Issued						84,517
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,185,798		7,988	(159,778)	1,339,024	$ 1,998,564
Stockholders' Equity Attributable to Parent	3,177,810
Stockholders' Equity Attributable to Noncontrolling Interest	$ 7,988
Common Stock, Dividends, Per Share, Cash Paid	$ 0.34
Net Income (Loss) Attributable to Parent	$ 84,590			0	84,590	$ 0
Net Income (Loss) Attributable to Noncontrolling Interest	187		187
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	84,777
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	2,934			2,934
Treasury Stock, Shares, Acquired						(127)
Payments for Repurchase of Common Stock	(14,886)			0	2,599	$ (17,485)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture						364
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	15,275		0	0	0	$ 15,275
Dividends, Common Stock, Cash	(28,823)		0	0	(28,823)	0
Noncontrolling Interest, Change in Redemption Value	(73)		(73)	0	0	$ 0
Shares, Issued						84,754
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,245,002
Stockholders' Equity Attributable to Parent	3,236,900			$ (156,844)	$ 1,397,390	$ 1,996,354
Stockholders' Equity Attributable to Noncontrolling Interest	$ 8,102		$ 8,102

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies(Notes)	3 Months Ended
	Jun. 30, 2019
Notes To Financial Statements [Abstract]
Nature of Operations	Nature of Operations and Summary of Significant Accounting Policies Nature of Operations On March 28, 2019, STERIS plc, a public limited company organized under the laws of England and Wales (“STERIS UK”), completed a redomiciliation from the United Kingdom to Ireland (the “Redomiciliation”). The Redomiciliation was achieved through the insertion of a new Irish public limited holding company (“STERIS plc”) on top of STERIS UK pursuant to a court-approved scheme of arrangement under English law (the “Scheme”). Following the Scheme effectiveness, STERIS UK was re-registered as a private limited company with the name STERIS Limited, and STERIS Emerald IE Limited, a company established in Ireland and a wholly-owned direct subsidiary of STERIS plc, was interposed as the direct parent company of STERIS UK. STERIS is a leading provider of infection prevention and other procedural products and services. Our focus is primarily on healthcare, pharmaceutical and medical device Customers. We offer Customers a unique mix of innovative capital equipment products, such as sterilizers and washers, surgical tables, lights and equipment management systems and connectivity solutions such as operating room integration; consumable products such as detergents and gastrointestinal endoscopy accessories and other products; and services, including capital equipment installation and maintenance, contract sterilization and microbial reduction of medical devices, instrument and scope repair solutions, laboratory services and instrument reprocessing. Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2019 dated May 30, 2019 . The Consolidated Balance Sheet at March 31, 2019 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2019 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2020. Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018 using the modified retrospective approach to contracts that were not completed as of April 1, 2018. Under this standard, certain capital equipment contracts are comprised of a single performance obligation, resulting in the deferral of the corresponding capital equipment revenue and cost of revenues until installation is complete. Previously, these capital equipment revenues and cost of revenues were recognized based upon shipping terms. We recorded a cumulative effect adjustment in the beginning of fiscal 2019 to Retained earnings of $5,637 , based on the current terms and conditions for certain open capital equipment contracts as of March 31, 2018. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2019, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization (GPO) agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to certain capital equipment products is deferred until installation is complete as the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare Products and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Healthcare Specialty Services segment, revenues relate primarily to outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2020, $39,484 of the March 31, 2019 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2019, $12,421 of the March 31, 2018 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancelable preventative maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2019, the transaction price allocated to remaining performance obligations was approximately $921,000 . We expect to recognize approximately 47% of the transaction price within one year and approximately 47% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2016-02, "Leases" (Topic 842) February 2016 The standard will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2020 We adopted this standard, and related amendments, effective April 1, 2019 using the modified retrospective transition method and have not restated prior periods. We elected to use the package of practical expedients permitted under the transition guidance, which allows the carry forward of historical lease classification of existing leases. We also elected the practical expedient related to land easements, allowing us to carry forward our accounting treatment for land easements on existing or expired agreements. We made an accounting policy election to not recognize lease assets or liabilities for leases with a term of 12 months or less and elected to not separate non-lease components from lease components to which they relate for all asset classes. We recorded lease right-of-use assets and lease liabilities for operating leases totaling $120,562. The adoption of the standard did not have a material impact to the Consolidated Statements of Income or Cash Flows. Additional information is disclosed in Note 8 under the heading "Leases". ASU 2017-12 "Targeted Improvements to Accounting for Hedging Activities" (Topic 815) August 2017 The standard provides targeted improvements to accounting for hedging activities by expanding an entity’s ability to hedge non-financial and financial risk components and reduce complexity in fair value hedges of interest rate risk. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted in any interim period after issuance of the standard. First Quarter Fiscal 2020 We adopted this standard effective April 1, 2019 with no material impact to our Consolidated Balance Sheets. The impact to our Consolidated Statements of Income will depend on the value of future hedging activities. ASU 2018-02 "Income Statement - Reporting Comprehensive Income" (Topic 220) February 2018 The standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act ("TCJA") and requires certain disclosures about stranded tax effects. The underlying guidance requiring that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. First Quarter Fiscal 2020 We have elected not to reclassify the income tax effects of the TCJA from Accumulated Other Comprehensive Income ("AOCI") to retained earnings.Our policy is to release income tax effects from AOCI when individual units of account are sold or terminated. Standards that have not yet been adopted ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" June 2016 The standard requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement” August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans" August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans. The standard also clarifies disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract" August 2018 The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2019 dated May 30, 2019 . Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2019 .

Inventories, Net (Notes)

Inventories, Net (Notes)	3 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: June 30, March 31, Raw materials $ 86,570 $ 83,009 Work in process 33,815 30,694 Finished goods 150,897 131,051 LIFO reserve (17,804 ) (16,757 ) Reserve for excess and obsolete inventory (19,891 ) (19,754 ) Inventories, net $ 233,587 $ 208,243

Property, Plant and Equipment (

Property, Plant and Equipment (Notes)	3 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows: June 30, March 31, Land and land improvements (1) $ 63,540 $ 63,522 Buildings and leasehold improvements 483,669 480,359 Machinery and equipment 654,901 656,956 Information systems 171,546 169,711 Radioisotope 501,293 483,080 Construction in progress (1) 157,343 133,689 Total property, plant, and equipment 2,032,292 1,987,317 Less: accumulated depreciation and depletion (978,075 ) (955,735 ) Property, plant, and equipment, net $ 1,054,217 $ 1,031,582 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

Debt (Notes)	3 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Debt	Debt Indebtedness was as follows: June 30, March 31, Credit Agreement $ 330,055 $ 301,846 Private Placement 883,739 884,967 Deferred financing costs (3,797 ) (3,619 ) Other 6 33 Total long term debt $ 1,210,003 $ 1,183,227 Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2019 dated May 30, 2019 .

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information (Notes)	3 Months Ended
	Jun. 30, 2019
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: June 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 29,316 $ 37,251 Accrued vacation/paid time off 10,371 10,191 Accrued bonuses 14,817 40,194 Accrued employee commissions 10,300 17,854 Other postretirement benefit obligations-current portion 1,633 1,633 Other employee benefit plans obligations-current portion 2,866 1,935 Total accrued payroll and other related liabilities $ 69,303 $ 109,058 Accrued expenses and other: Deferred revenues $ 52,614 $ 55,333 Service liabilities 41,256 42,101 Self-insured risk reserves-current portion 8,412 6,537 Accrued dealer commissions 15,736 15,283 Accrued warranty 6,906 7,194 Asset retirement obligation-current portion 2,698 2,656 Other 55,182 58,661 Total accrued expenses and other $ 182,804 $ 187,765 Other liabilities: Self-insured risk reserves-long-term portion $ 14,445 $ 14,445 Other postretirement benefit obligations-long-term portion 10,139 10,918 Defined benefit pension plans obligations-long-term portion 16,693 16,168 Other employee benefit plans obligations-long-term portion 2,551 4,711 Accrued long-term income taxes 13,524 13,515 Asset retirement obligation-long-term portion 9,755 9,730 Other 17,964 18,325 Total other liabilities $ 85,071 $ 87,812

Income Tax Expense (Notes)

Income Tax Expense (Notes)	3 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Expense	Income Tax Expense The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduced the U.S. federal corporate income tax rate to 21.0% , required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA. We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments. The effective income tax rates for the three month periods ended June 30, 2019 and 2018 were 14.7% and 15.4% , respectively. The decrease in the fiscal 2020 rate compared to the prior year period is primarily attributable to an increase in favorable discrete items. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2013. We remain subject to tax authority audits in various jurisdictions wherever we do business. In May 2019, we received two notices of proposed tax adjustment from the U.S. Internal Revenue Service (the “IRS”) regarding the deductibility of interest paid on certain intercompany debt. The notices relate to fiscal years 2016 and 2017. The IRS adjustment would result in a tax liability of approximately $25,000 . We are contesting the IRS’s assertions, and intend to pursue available remedies such as appeals and litigation, if necessary. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.

Contingencies (Notes)

Contingencies (Notes)	3 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. On May 31, 2012, our Albert Browne Limited subsidiary received a warning letter from the FDA regarding chemical indicators manufactured in the United Kingdom. These devices are intended for the monitoring of certain sterilization and other processes. The FDA warning letter states that the agency has concerns regarding operational business processes. We do not believe that the FDA's concerns are related to product performance, or that they result from Customer complaints. We have reviewed our processes with the agency and finalized our remediation measures, and are awaiting FDA reinspection. We do not currently believe that the impact of this event will have a material adverse effect on our financial results. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2019 dated May 30, 2019: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims". From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q. Leases We lease manufacturing, warehouse and office space, service facilities, vehicles, equipment and communication systems. Certain leases contain options that provide us with the ability to extend the lease term. Such options are included in the lease term when it is reasonably certain that the option will be exercised. We made an accounting policy election to not recognize lease assets or lease liabilities for leases with a lease term of twelve months or less. We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in property, plant and equipment, net and the liabilities are included in other liabilities. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of the asset. Our finance leases are not material as of June 30, 2019 and for the three-month period then ended. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, lease term, as well as publicly available data for instruments with similar characteristics. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. When accounting for leases, we combine payments for leased assets, related services and other components of a lease. The components of operating lease expense are as follows: Three Months Ended June 30, 2019 Fixed operating lease expense 7,049 Variable operating lease expense 1,014 Total operating lease expense $ 8,063 Supplemental cash flow information related to operating leases are as follows: Three Months Ended June 30, 2019 Cash paid for amounts included in the measurement of operating lease liabilities 6,880 Right-of-use assets obtained in exchange for operating lease obligations 8,506 Maturities of lease liabilities at June 30, 2019 are as follows : June 30, 2019 Remainder of 2020: $ 19,608 2021 20,882 2022 16,377 2023 13,920 2024 11,645 2025 and thereafter 78,771 Total operating lease payments 161,203 Less imputed interest 38,576 Total operating lease liabilities $ 122,627 Supplemental information related to operating leases are as follows: June 30, 2019 Weighted-average remaining lease term of operating leases 0.9 years Weighted-average discount rate of operating leases 4.6 % Prior to the adoption of ASU 2016-02, " Leases" (Topic 842) future minimum annual rentals payable under noncancelable operating lease agreements in excess of one year as of March 31, 2019 were as follows: March 31, 2019 2020 $ 24,008 2021 18,567 2022 13,917 2023 11,929 2024 and thereafter 93,939 Total minimum lease payments $ 162,360 In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2019 foreign currency exchange rates.

Business Segment Information (N

Business Segment Information (Notes)	3 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information We operate and report our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare Products segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. Our Healthcare Specialty Services segment provides a range of specialty services for healthcare providers including hospital sterilization services, and instrument and scope repairs. Our Life Sciences segment offers consumable products, equipment maintenance, specialty services and capital equipment for pharmaceutical manufacturers and research facilities. Our Applied Sterilization Technologies segment offers contract sterilization and laboratory services for medical device and pharmaceutical Customers and others. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. For the three months ended June 30, 2019 , revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2019 , dated May 30, 2019 . Financial information for each of our segments is presented in the following table: Three Months Ended June 30, 2019 2018 Revenues: Healthcare Products $ 309,787 $ 292,010 Healthcare Specialty Services 135,945 122,249 Life Sciences 96,785 84,955 Applied Sterilization Technologies 154,286 139,544 Total revenues $ 696,803 $ 638,758 Operating income (loss): Healthcare Products $ 73,698 $ 61,722 Healthcare Specialty Services 16,817 12,954 Life Sciences 33,039 29,865 Applied Sterilization Technologies 68,035 56,151 Corporate (55,397 ) (46,042 ) Total operating income before adjustments $ 136,192 $ 114,650 Less: Adjustments Amortization of acquired intangible assets (1) $ 16,949 $ 18,055 Acquisition and integration related charges (2) 1,917 1,671 Redomiciliation and tax restructuring costs (3) 1,770 287 (Gain) on fair value adjustment of acquisition related contingent consideration (1) — (842 ) Net loss on divestiture of businesses (1) 2,426 444 Amortization of property "step up" to fair value (1) 735 611 Restructuring charges (4) 2,307 — Total operating income $ 110,088 $ 94,424 (1) For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2019 , dated May 30, 2019 . (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in connection with the Redomiciliation. (4) For more information regarding our restructuring activities see Note 2 titled, "Restructuring". Additional information regarding our fiscal 2020 and fiscal 2019 first quarter revenue is disclosed in the following tables: Three Months Ended June 30, 2019 2018 Healthcare Products: Capital equipment $ 115,196 $ 107,496 Consumables 108,782 100,414 Service 85,809 84,100 Total Healthcare Products Revenues $ 309,787 $ 292,010 Total Healthcare Specialty Services Revenues $ 135,945 $ 122,249 Life Sciences: Capital equipment $ 26,769 $ 19,114 Consumables 44,029 40,221 Service 25,987 25,620 Total Life Sciences Revenues $ 96,785 $ 84,955 Applied Sterilization Technologies Service Revenues $ 154,286 $ 139,544 Total Revenues $ 696,803 $ 638,758 Three Months Ended June 30, 2019 2018 Revenues: Ireland $ 15,108 $ 12,560 United States 511,152 447,540 Other locations 170,543 178,658 Total Revenues $ 696,803 $ 638,758

Shares and Preferred Shares (No

Shares and Preferred Shares (Notes)	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Ordinary shares In connection with the Redomiciliation, STERIS UK shareholders received STERIS plc shares pursuant to a scheme of arrangement under UK law. Each STERIS UK ordinary shareholder received one ordinary share, par value $75.00 , of STERIS plc for each STERIS UK ordinary share held, which STERIS UK shares were canceled. On May 3, 2019, the par value of STERIS plc shares issued pursuit to the scheme of arrangement was reduced to $0.001 per share. We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended June 30, Denominator (shares in thousands): 2019 2018 Weighted average shares outstanding—basic 84,638 84,685 Dilutive effect of share equivalents 928 824 Weighted average shares outstanding and share equivalents—diluted 85,566 85,509 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended June 30, (shares in thousands) 2019 2018 Number of share options 122 141 Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Repurchases of Shares (Notes)

Repurchases of Shares (Notes)	3 Months Ended
	Jun. 30, 2019
Notes To Financial Statements [Abstract]
Repurchases of shares	Repurchases of Ordinary Shares On August 9, 2016, STERIS UK announced that its Board of Directors had authorized the purchase of up to $300,000 (net of taxes, fees and commissions) of our ordinary shares. As a result of the Redomiciliation, that share repurchase authorization terminated. On May 7, 2019, our Board of Directors authorized the continuation of the share repurchase program by STERIS plc. As of June 30, 2019, there was approximately $70,367 (net of taxes, fees and commissions) of remaining availability under the authorization. On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). Under the authorizations, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any repurchase program may be activated, suspended or discontinued at any time. During the first three months of fiscal 2020, we repurchased 60,000 of our ordinary shares for the aggregate amount of $8,612 (net of fees and commissions) pursuant to this authorization. During the first three months of fiscal 2020 , we obtained 66,745 of our ordinary shares in the aggregate amount of $7,446 in connection with share based compensation award programs. During the first three months of fiscal 2019, we obtained 89,730 of our ordinary shares in the aggregate amount of $7,753

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	3 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the option plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of June 30, 2019 , 3,931,008 ordinary shares remained available for grant under the long-term incentive plan. The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first three months of fiscal 2020 and 2019: Fiscal 2020 Fiscal 2019 Risk-free interest rate 2.27 % 2.62 % Expected life of options 6.2 years 6.2 years Expected dividend yield of stock 1.23 % 1.48 % Expected volatility of stock 20.27 % 19.83 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.77% and 2.37% was applied in fiscal 2020 and 2019 , respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2019 2,104,685 $ 72.82 Granted 334,236 147.05 Exercised (217,543 ) 49.45 Forfeited (667 ) 72.57 Outstanding at June 30, 2019 2,220,711 $ 86.28 7.2 years $ 139,012 Exercisable at June 30, 2019 1,304,982 $ 66.33 6.0 years $ 107,729 We estimate that 880,401 of the non-vested stock options outstanding at June 30, 2019 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $148.88 closing price of our ordinary shares on June 30, 2019 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first three months of fiscal 2020 and fiscal 2019 was $18,843 and $4,582 , respectively. Net cash proceeds from the exercise of stock options were $9,899 and $3,435 for the first three months of fiscal 2020 and fiscal 2019 , respectively. The weighted average grant date fair value of stock option grants was $23.19 and $17.53 for the first three months of fiscal 2020 and fiscal 2019 , respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of June 30, 2019 and 2018 was $610 and $1,089 , respectively. A summary of the non-vested restricted share and share unit activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2019 676,373 33,219 $ 80.86 Granted 138,460 6,540 133.68 Vested (161,652 ) (7,746 ) 71.63 Forfeited (8,717 ) (554 ) 83.89 Non-vested at June 30, 2019 644,464 31,459 $ 94.48 Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first three months of fiscal 2020 was $12,134 . As of June 30, 2019 , there was a total of $58,089 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.43 years .

Financial and Other Guarantees(

Financial and Other Guarantees(Notes)	3 Months Ended
	Jun. 30, 2019
Product Warranties Disclosures [Abstract]
Product Warranty Disclosure	Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first three months of fiscal 2020 were as follows: Warranties Balance, March 31, 2019 $ 7,194 Warranties issued during the period 2,496 Settlements made during the period (2,784 ) Balance, June 30, 2019 $ 6,906

Deritvatives and Hedging (Notes

Deritvatives and Hedging (Notes)	3 Months Ended
	Jun. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure	Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the first quarter of fiscal 2020, we also entered into forward foreign currency contracts in order to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2020. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At June 30, 2019 , we held foreign currency forward contracts to buy 194.9 million Mexican pesos, 16.8 million Canadian dollars; and to sell 10.8 million euros. At June 30, 2019 we held commodity swap contracts to buy 506 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location June 30, 2019 March 31, 2019 June 30, 2019 March 31, 2019 Prepaid & Other $ 597 $ 552 $ — $ — Accrued expenses and other $ — $ — $ 174 $ 278 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended June 30, 2019 2018 Foreign currency forward contracts Selling, general and administrative $ 406 $ (358 ) Commodity swap contracts Cost of revenues $ (127 ) $ 364 Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $47,800 at June 30, 2019 . These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	3 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at June 30, 2019 and March 31, 2019 : Fair Value Measurements Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 June 30, March 31, June 30, March 31, June 30, March 31, June 30, March 31, Assets: Cash and cash equivalents $ 238,067 $ 220,633 $ 238,067 $ 220,633 $ — $ — $ — $ — Forward and swap contracts (1) 597 552 — — 597 552 — — Equity investments (2) 11,980 13,873 11,980 13,873 — — — — — — Other investments 2,579 2,545 2,579 2,545 — — — — Liabilities: Forward and swap contracts (1) $ 174 $ 278 $ — $ — $ 174 $ 278 $ — $ — Deferred compensation plans (2) 1,598 1,564 1,598 1,564 — — — — Long term debt (3) 1,210,003 1,183,227 — — 1,250,848 1,200,558 — — Contingent consideration obligations (4) 5,991 5,950 — — — — 5,991 5,950 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2020 and 2019, we recorded losses of $1,758 and $1,377 , respectively, related to these investments. (3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2019 are summarized as follows: Contingent Consideration Balance at March 31, 2019 $ 5,950 Additions 45 Currency translation adjustments (4 ) Balance at June 30, 2019 $ 5,991

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Jun. 30, 2019
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2019 and 2018 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2019 $ (4,204 ) $ (155,574 ) $ (159,778 ) Other Comprehensive (Loss) Income before reclassifications 190 3,439 3,629 Amounts reclassified from Accumulated Other Comprehensive (Loss) Income (695 ) — (695 ) Net current-period Other Comprehensive (Loss) Income (505 ) 3,439 2,934 Balance at June 30, 2019 $ (4,709 ) $ (152,135 ) $ (156,844 ) (1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Gain (Loss) on Available for Sale Securities Defined Benefit Plans (2) Currency Translation (3) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2018 $ 1,970 $ (6,742 ) $ 16,457 $ 11,685 Other Comprehensive Income (Loss) before reclassifications — 153 (130,401 ) (130,248 ) Amounts reclassified from Accumulated Other Comprehensive (Loss) — (563 ) — (563 ) Net current-period Other Comprehensive (Loss) — (410 ) (130,401 ) (130,811 ) Cumulative adjustment to Retained Earnings (1) (1,970 ) — — (1,970 ) Balance at June 30, 2018 $ — $ (7,152 ) $ (113,944 ) $ (121,096 ) (1) As a result of the adoption of ASC 2016-01, we recorded a cumulative effect adjustment to our opening fiscal 2019 retained earnings balance that increased retained earnings and decreased accumulated other comprehensive income. Refer to our Annual Report filed on Form 10-K for the year ended March 31, 2019, for more information. (2) Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (3) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.

Loans Receivable (Notes)

Loans Receivable (Notes)	3 Months Ended
	Jun. 30, 2019
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	18. Loans Receivable In connection with an equity investment of $4,955 , we agreed to provide a credit facility of up to approximately $10,000 for a term of up to seven years ending in 2025. The loan carries an interest rate of 4% compounded daily and payable annually. Outstanding borrowings under the agreement totaled $7,638 at June 30, 2019 and $7,465 at March 31, 2019. In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carries an interest rate of 4% for the first four years and 12% thereafter. Outstanding borrowings under the agreement totaled $8,606 (or €7,567 ) at June 30, 2019 and $8,494 (or €7,550 ) at March 31, 2019.

Restructuring (Notes)

Restructuring (Notes)	3 Months Ended
	Jun. 30, 2019
Restructuring [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Restructuring Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions are being eliminated. The Company will relocate the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions are designed to enhance profitability and improve efficiency. Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $43,015 related to these restructuring actions, of which $32,376 was recorded as restructuring expenses and $10,639 was recorded in cost of revenues, with a total of $30,713 , $2,518 , $668 and $7,798 related to the Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies segments, respectively. Corporate related restructuring charges were $1,318 . Additional restructuring expenses related to this plan are not expected to be material to our results of operations. The following table summarizes our total pre-tax restructuring expenses for fiscal 2020: Three months ended June 30, 2019 Fiscal 2019 Restructuring Plan Severance and other compensation related costs $ 1,091 Lease termination costs and other 298 Product rationalization (1) 918 Total restructuring expenses $ 2,307 (1) Recorded in cost of revenues on the Consolidated Statements of Income. Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The following table summarizes our restructuring liability balances: Fiscal 2019 Restructuring Plan March 31, Provisions Payments (1) June 30, Severance and termination benefits $ 4,102 $ 1,091 $ (1,570 ) $ 3,623 Lease termination obligations and other 2,029 2 (289 ) 1,742 Total $ 6,131 — $ 1,093 — $ (1,859 ) — $ 5,365 (1) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2019 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2020.
Recently Issued Accounting Standards Impacting the Company	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have recently been adopted ASU 2016-02, "Leases" (Topic 842) February 2016 The standard will require lessees to record all leases, whether finance or operating, on the balance sheet. An asset will be recorded to represent the right to use the leased asset, and a liability will be recorded to represent the lease obligation. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within that period. Early adoption is permitted. First Quarter Fiscal 2020 We adopted this standard, and related amendments, effective April 1, 2019 using the modified retrospective transition method and have not restated prior periods. We elected to use the package of practical expedients permitted under the transition guidance, which allows the carry forward of historical lease classification of existing leases. We also elected the practical expedient related to land easements, allowing us to carry forward our accounting treatment for land easements on existing or expired agreements. We made an accounting policy election to not recognize lease assets or liabilities for leases with a term of 12 months or less and elected to not separate non-lease components from lease components to which they relate for all asset classes. We recorded lease right-of-use assets and lease liabilities for operating leases totaling $120,562. The adoption of the standard did not have a material impact to the Consolidated Statements of Income or Cash Flows. Additional information is disclosed in Note 8 under the heading "Leases". ASU 2017-12 "Targeted Improvements to Accounting for Hedging Activities" (Topic 815) August 2017 The standard provides targeted improvements to accounting for hedging activities by expanding an entity’s ability to hedge non-financial and financial risk components and reduce complexity in fair value hedges of interest rate risk. The guidance eliminates the requirement to separately measure and report hedge ineffectiveness and generally requires the entire change in the fair value of a hedging instrument to be presented in the same income statement line as the hedged item. The guidance also eases certain documentation and assessment requirements and modifies the accounting for components excluded from the assessment of hedge effectiveness. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted in any interim period after issuance of the standard. First Quarter Fiscal 2020 We adopted this standard effective April 1, 2019 with no material impact to our Consolidated Balance Sheets. The impact to our Consolidated Statements of Income will depend on the value of future hedging activities. ASU 2018-02 "Income Statement - Reporting Comprehensive Income" (Topic 220) February 2018 The standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act ("TCJA") and requires certain disclosures about stranded tax effects. The underlying guidance requiring that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This standard is effective for fiscal years beginning after December 15, 2018 and interim periods within those years. Early adoption is permitted. First Quarter Fiscal 2020 We have elected not to reclassify the income tax effects of the TCJA from Accumulated Other Comprehensive Income ("AOCI") to retained earnings.Our policy is to release income tax effects from AOCI when individual units of account are sold or terminated. Standards that have not yet been adopted ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" June 2016 The standard requires a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. N/A We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement” August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans" August 2018 The standard modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans. The standard also clarifies disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements as it modifies disclosure requirements only. ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract" August 2018 The standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years ending after December 15, 2019 and early adoption is permitted. N/A We do not expect this standard to have a material impact on our consolidated financial statements.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018 using the modified retrospective approach to contracts that were not completed as of April 1, 2018. Under this standard, certain capital equipment contracts are comprised of a single performance obligation, resulting in the deferral of the corresponding capital equipment revenue and cost of revenues until installation is complete. Previously, these capital equipment revenues and cost of revenues were recognized based upon shipping terms. We recorded a cumulative effect adjustment in the beginning of fiscal 2019 to Retained earnings of $5,637 , based on the current terms and conditions for certain open capital equipment contracts as of March 31, 2018. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2019, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization (GPO) agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to certain capital equipment products is deferred until installation is complete as the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare Products and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Healthcare Specialty Services segment, revenues relate primarily to outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2020, $39,484 of the March 31, 2019 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2019, $12,421 of the March 31, 2018 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancelable preventative maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2019, the transaction price allocated to remaining performance obligations was approximately $921,000 . We expect to recognize approximately 47% of the transaction price within one year and approximately 47% beyond one year. The remainder has yet to be scheduled for delivery.

Contingencies Lease (Policies)

Contingencies Lease (Policies)	3 Months Ended
	Jun. 30, 2019
Statement of Financial Position [Abstract]
Lessee, Leases [Policy Text Block]	We lease manufacturing, warehouse and office space, service facilities, vehicles, equipment and communication systems. Certain leases contain options that provide us with the ability to extend the lease term. Such options are included in the lease term when it is reasonably certain that the option will be exercised. We made an accounting policy election to not recognize lease assets or lease liabilities for leases with a lease term of twelve months or less. We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in property, plant and equipment, net and the liabilities are included in other liabilities. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of the asset. Our finance leases are not material as of June 30, 2019 and for the three-month period then ended. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, lease term, as well as publicly available data for instruments with similar characteristics. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. When accounting for leases, we combine payments for leased assets, related services and other components of a lease.

Inventories, Net Inventories, N

Inventories, Net Inventories, Net (Tables)	3 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory costs include material, labor, and overhead. Inventories, net consisted of the following: June 30, March 31, Raw materials $ 86,570 $ 83,009 Work in process 33,815 30,694 Finished goods 150,897 131,051 LIFO reserve (17,804 ) (16,757 ) Reserve for excess and obsolete inventory (19,891 ) (19,754 ) Inventories, net $ 233,587 $ 208,243

Property, Plant and Equipment P

Property, Plant and Equipment Property, Plant and Equipment (Tables)	3 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: June 30, March 31, Land and land improvements (1) $ 63,540 $ 63,522 Buildings and leasehold improvements 483,669 480,359 Machinery and equipment 654,901 656,956 Information systems 171,546 169,711 Radioisotope 501,293 483,080 Construction in progress (1) 157,343 133,689 Total property, plant, and equipment 2,032,292 1,987,317 Less: accumulated depreciation and depletion (978,075 ) (955,735 ) Property, plant, and equipment, net $ 1,054,217 $ 1,031,582 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Tables)

Debt Debt (Tables)	3 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: June 30, March 31, Credit Agreement $ 330,055 $ 301,846 Private Placement 883,739 884,967 Deferred financing costs (3,797 ) (3,619 ) Other 6 33 Total long term debt $ 1,210,003 $ 1,183,227

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)	3 Months Ended
	Jun. 30, 2019
Notes To Financial Statements [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: June 30, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 29,316 $ 37,251 Accrued vacation/paid time off 10,371 10,191 Accrued bonuses 14,817 40,194 Accrued employee commissions 10,300 17,854 Other postretirement benefit obligations-current portion 1,633 1,633 Other employee benefit plans obligations-current portion 2,866 1,935 Total accrued payroll and other related liabilities $ 69,303 $ 109,058 Accrued expenses and other: Deferred revenues $ 52,614 $ 55,333 Service liabilities 41,256 42,101 Self-insured risk reserves-current portion 8,412 6,537 Accrued dealer commissions 15,736 15,283 Accrued warranty 6,906 7,194 Asset retirement obligation-current portion 2,698 2,656 Other 55,182 58,661 Total accrued expenses and other $ 182,804 $ 187,765 Other liabilities: Self-insured risk reserves-long-term portion $ 14,445 $ 14,445 Other postretirement benefit obligations-long-term portion 10,139 10,918 Defined benefit pension plans obligations-long-term portion 16,693 16,168 Other employee benefit plans obligations-long-term portion 2,551 4,711 Accrued long-term income taxes 13,524 13,515 Asset retirement obligation-long-term portion 9,755 9,730 Other 17,964 18,325 Total other liabilities $ 85,071 $ 87,812

Contingencies Leases (Tables)

Contingencies Leases (Tables)	3 Months Ended
	Jun. 30, 2019
Statement of Financial Position [Abstract]
Schedule of Rent Expense [Table Text Block]	The components of operating lease expense are as follows: Three Months Ended June 30, 2019 Fixed operating lease expense 7,049 Variable operating lease expense 1,014 Total operating lease expense $ 8,063
Lessee, Operating Lease, Disclosure [Table Text Block]	Supplemental cash flow information related to operating leases are as follows: Three Months Ended June 30, 2019 Cash paid for amounts included in the measurement of operating lease liabilities 6,880 Right-of-use assets obtained in exchange for operating lease obligations 8,506
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturities of lease liabilities at June 30, 2019 are as follows : June 30, 2019 Remainder of 2020: $ 19,608 2021 20,882 2022 16,377 2023 13,920 2024 11,645 2025 and thereafter 78,771 Total operating lease payments 161,203 Less imputed interest 38,576 Total operating lease liabilities $ 122,627 Supplemental information related to operating leases are as follows: June 30, 2019 Weighted-average remaining lease term of operating leases 0.9 years Weighted-average discount rate of operating leases 4.6 % Prior to the adoption of ASU 2016-02, " Leases" (Topic 842) future minimum annual rentals payable under noncancelable operating lease agreements in excess of one year as of March 31, 2019 were as follows: March 31, 2019 2020 $ 24,008 2021 18,567 2022 13,917 2023 11,929 2024 and thereafter 93,939 Total minimum lease payments $ 162,360 In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2019 foreign currency exchange rates.

Business Segment Information Bu

Business Segment Information Business Segment Information (Tables)	3 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Financial information for each of our segments is presented in the following table: Three Months Ended June 30, 2019 2018 Revenues: Healthcare Products $ 309,787 $ 292,010 Healthcare Specialty Services 135,945 122,249 Life Sciences 96,785 84,955 Applied Sterilization Technologies 154,286 139,544 Total revenues $ 696,803 $ 638,758 Operating income (loss): Healthcare Products $ 73,698 $ 61,722 Healthcare Specialty Services 16,817 12,954 Life Sciences 33,039 29,865 Applied Sterilization Technologies 68,035 56,151 Corporate (55,397 ) (46,042 ) Total operating income before adjustments $ 136,192 $ 114,650 Less: Adjustments Amortization of acquired intangible assets (1) $ 16,949 $ 18,055 Acquisition and integration related charges (2) 1,917 1,671 Redomiciliation and tax restructuring costs (3) 1,770 287 (Gain) on fair value adjustment of acquisition related contingent consideration (1) — (842 ) Net loss on divestiture of businesses (1) 2,426 444 Amortization of property "step up" to fair value (1) 735 611 Restructuring charges (4) 2,307 — Total operating income $ 110,088 $ 94,424
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended June 30, 2019 2018 Healthcare Products: Capital equipment $ 115,196 $ 107,496 Consumables 108,782 100,414 Service 85,809 84,100 Total Healthcare Products Revenues $ 309,787 $ 292,010 Total Healthcare Specialty Services Revenues $ 135,945 $ 122,249 Life Sciences: Capital equipment $ 26,769 $ 19,114 Consumables 44,029 40,221 Service 25,987 25,620 Total Life Sciences Revenues $ 96,785 $ 84,955 Applied Sterilization Technologies Service Revenues $ 154,286 $ 139,544 Total Revenues $ 696,803 $ 638,758
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended June 30, 2019 2018 Revenues: Ireland $ 15,108 $ 12,560 United States 511,152 447,540 Other locations 170,543 178,658 Total Revenues $ 696,803 $ 638,758

Shares and Preferred Shares Sha

Shares and Preferred Shares Shares and Preferred Shares (Tables)	3 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended June 30, Denominator (shares in thousands): 2019 2018 Weighted average shares outstanding—basic 84,638 84,685 Dilutive effect of share equivalents 928 824 Weighted average shares outstanding and share equivalents—diluted 85,566 85,509
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended June 30, (shares in thousands) 2019 2018 Number of share options 122 141

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Tables)	3 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Assumptions Used	The following weighted-average assumptions were used for options granted during the first three months of fiscal 2020 and 2019: Fiscal 2020 Fiscal 2019 Risk-free interest rate 2.27 % 2.62 % Expected life of options 6.2 years 6.2 years Expected dividend yield of stock 1.23 % 1.48 % Expected volatility of stock 20.27 % 19.83 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Options Weighted Average Exercise Price Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at March 31, 2019 2,104,685 $ 72.82 Granted 334,236 147.05 Exercised (217,543 ) 49.45 Forfeited (667 ) 72.57 Outstanding at June 30, 2019 2,220,711 $ 86.28 7.2 years $ 139,012 Exercisable at June 30, 2019 1,304,982 $ 66.33 6.0 years $ 107,729
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	ly. A summary of the non-vested restricted share and share unit activity is presented below: Number of Restricted Shares Number of Restricted Share Units Weighted-Average Grant Date Fair Value Non-vested at March 31, 2019 676,373 33,219 $ 80.86 Granted 138,460 6,540 133.68 Vested (161,652 ) (7,746 ) 71.63 Forfeited (8,717 ) (554 ) 83.89 Non-vested at June 30, 2019 644,464 31,459 $ 94.48

Financial and Other Guarantees

Financial and Other Guarantees Financial and Other Gurantees (Tables)	3 Months Ended
	Jun. 30, 2019
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	Changes in our warranty liability during the first three months of fiscal 2020 were as follows: Warranties Balance, March 31, 2019 $ 7,194 Warranties issued during the period 2,496 Settlements made during the period (2,784 ) Balance, June 30, 2019 $ 6,906

Derivatives and Hedging Derivat

Derivatives and Hedging Derivatives and Hedging (Tables)	3 Months Ended
	Jun. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location June 30, 2019 March 31, 2019 June 30, 2019 March 31, 2019 Prepaid & Other $ 597 $ 552 $ — $ — Accrued expenses and other $ — $ — $ 174 $ 278
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) recognized in income Amount of gain (loss) recognized in income Three Months Ended June 30, 2019 2018 Foreign currency forward contracts Selling, general and administrative $ 406 $ (358 ) Commodity swap contracts Cost of revenues $ (127 ) $ 364

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The following table shows the fair value of our financial assets and liabilities at June 30, 2019 and March 31, 2019 : Fair Value Measurements Carrying Value Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Level 1 Level 2 Level 3 June 30, March 31, June 30, March 31, June 30, March 31, June 30, March 31, Assets: Cash and cash equivalents $ 238,067 $ 220,633 $ 238,067 $ 220,633 $ — $ — $ — $ — Forward and swap contracts (1) 597 552 — — 597 552 — — Equity investments (2) 11,980 13,873 11,980 13,873 — — — — — — Other investments 2,579 2,545 2,579 2,545 — — — — Liabilities: Forward and swap contracts (1) $ 174 $ 278 $ — $ — $ 174 $ 278 $ — $ — Deferred compensation plans (2) 1,598 1,564 1,598 1,564 — — — — Long term debt (3) 1,210,003 1,183,227 — — 1,250,848 1,200,558 — — Contingent consideration obligations (4) 5,991 5,950 — — — — 5,991 5,950 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2020 and 2019, we recorded losses of $1,758 and $1,377 , respectively, related to these investments. (3) We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2019 are summarized as follows: Contingent Consideration Balance at March 31, 2019 $ 5,950 Additions 45 Currency translation adjustments (4 ) Balance at June 30, 2019 $ 5,991

Reclassifications out of Accu_2

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Jun. 30, 2019
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2019 and 2018 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2019 $ (4,204 ) $ (155,574 ) $ (159,778 ) Other Comprehensive (Loss) Income before reclassifications 190 3,439 3,629 Amounts reclassified from Accumulated Other Comprehensive (Loss) Income (695 ) — (695 ) Net current-period Other Comprehensive (Loss) Income (505 ) 3,439 2,934 Balance at June 30, 2019 $ (4,709 ) $ (152,135 ) $ (156,844 ) (1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. Gain (Loss) on Available for Sale Securities Defined Benefit Plans (2) Currency Translation (3) Total Accumulated Other Comprehensive Income (Loss) Balance at March 31, 2018 $ 1,970 $ (6,742 ) $ 16,457 $ 11,685 Other Comprehensive Income (Loss) before reclassifications — 153 (130,401 ) (130,248 ) Amounts reclassified from Accumulated Other Comprehensive (Loss) — (563 ) — (563 ) Net current-period Other Comprehensive (Loss) — (410 ) (130,401 ) (130,811 ) Cumulative adjustment to Retained Earnings (1) (1,970 ) — — (1,970 ) Balance at June 30, 2018 $ — $ (7,152 ) $ (113,944 ) $ (121,096 ) (1) As a result of the adoption of ASC 2016-01, we recorded a cumulative effect adjustment to our opening fiscal 2019 retained earnings balance that increased retained earnings and decreased accumulated other comprehensive income. Refer to our Annual Report filed on Form 10-K for the year ended March 31, 2019, for more information. (2) Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (3)

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Jun. 30, 2019
Restructuring [Abstract]
Restructuring and Related Costs [Table Text Block]	The following table summarizes our total pre-tax restructuring expenses for fiscal 2020: Three months ended June 30, 2019 Fiscal 2019 Restructuring Plan Severance and other compensation related costs $ 1,091 Lease termination costs and other 298 Product rationalization (1) 918 Total restructuring expenses $ 2,307
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	Fiscal 2019 Restructuring Plan March 31, Provisions Payments (1) June 30, Severance and termination benefits $ 4,102 $ 1,091 $ (1,570 ) $ 3,623 Lease termination obligations and other 2,029 2 (289 ) 1,742 Total $ 6,131 — $ 1,093 — $ (1,859 ) — $ 5,365 (1) Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies Revenue Intial Application period (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Property, Plant and Equipment [Line Items]
Deferred Revenue, Revenue Recognized	$ 39,484	$ 12,421

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Apr. 01, 2018	Mar. 31, 2018
Assets	$ 5,229,723		$ 5,073,071
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification		$ 5,637
Deferred Revenue, Revenue Recognized	39,484	12,421
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,245,002	$ 3,099,188	3,185,798		$ 3,217,300
Liabilities	1,984,721		1,887,273
Accounts Receivable, after Allowance for Credit Loss, Current	509,655		564,830
Inventory, Net	233,587		208,243
Other Prepaid Expense, Current	62,973		60,029
Accrued Liabilities, Current	182,804		187,765
Retained Earnings (Accumulated Deficit)	1,397,390		$ 1,339,024
Revenue, Remaining Performance Obligation, Amount	921,000
Assets [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	120,562
Equity [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				$ 5,637
Liability [Member]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	$ 120,562
Expected recognition within the next year [Member]
Revenue, Remaining Performance Obligation, Percentage	47.00%
Expected recognition beyond the next year [Member] [Member]
Revenue, Remaining Performance Obligation, Percentage	47.00%

Business Acquisitions and Dives

Business Acquisitions and Divestitures Fiscal 2018 Acquisitions (Details) $ in Thousands	Jun. 30, 2019USD ($)
Series of Individually Immaterial Business Acquisitions
Business Acquisition [Line Items]
Approximate purchase price of entity	$ 34,970

Business Acquisitions and Div_2

Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Business Acquisition [Line Items]
Revenues	$ 696,803	$ 638,758
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 2,347,329		$ 2,322,928

Business Acquisitions and Div_3

Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) - USD ($) $ in Thousands		3 Months Ended		12 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues		$ 696,803	$ 638,758
Proceeds from sale of business		(439)
Pre-tax gain or loss on sale of business	[1]	$ 2,426	$ 444
Years 1-4, 4% Int Rate
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate		4.00%
Years 5-15, 12% Int Rate
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Interest rate		12.00%
China HCS [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax gain or loss on sale of business		$ (2,295)
HCS China Divestiture [Domain]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenues				$ 5,000
[1]	For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2019 , dated May 30, 2019 .

Inventories, Net Inventories,_2

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Raw materials	$ 86,570	$ 83,009
Work in process	33,815	30,694
Finished goods	150,897	131,051
LIFO reserve	(17,804)	(16,757)
Reserve for excess and obsolete inventory	(19,891)	(19,754)
Inventories, net	$ 233,587	$ 208,243

Property, Plant and Equipment_2

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Property, Plant and Equipment [Line Items]
Land and land improvements	$ 63,540	$ 63,522
Buildings and leasehold improvements	483,669	480,359
Machinery and equipment	654,901	656,956
Information systems	171,546	169,711
Radioisotope	501,293	483,080
Construction in progress	157,343	133,689
Total property, plant, and equipment	2,032,292	1,987,317
Less: accumulated depreciation and depletion	(978,075)	(955,735)
Property, plant, and equipment, net	$ 1,054,217	$ 1,031,582

Debt Debt (Details)

Debt Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
Private Placement	$ 883,739	$ 884,967
Deferred financing costs	3,797	3,619
Other Long-term Debt	6	33
Credit Agreement	330,055	301,846
Total long term debt	$ 1,210,003	$ 1,183,227

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Mar. 31, 2019
Accrued payroll and other related liabilities:
Compensation and related items	$ 29,316	$ 37,251
Accrued vacation/paid time off	10,371	10,191
Accrued bonuses	14,817	40,194
Accrued employee commissions	10,300	17,854
Other postretirement benefit obligations-current portion	1,633	1,633
Other employee benefit plans obligations-current portion	2,866	1,935
Total accrued payroll and other related liabilities	69,303	109,058
Accrued expenses and other:
Deferred revenues	52,614	55,333
Service liabilities	41,256	42,101
Self-insured risk reserves-current portion	8,412	6,537
Accrued dealer commissions	15,736	15,283
Accrued warranty	6,906	7,194
Asset retirement obligation-current portion	2,698	2,656
Other	55,182	58,661
Total accrued expenses and other	182,804	187,765
Other liabilities:
Self-insured risk reserves-long-term portion	14,445	14,445
Other postretirement benefit obligations-long-term portion	10,139	10,918
Defined benefit pension plans obligations-long-term portion	16,693	16,168
Other employee benefit plans obligations-long-term portion	2,551	4,711
Accrued long-term income taxes	13,524	13,515
Asset retirement obligation-long-term portion	9,755	9,730
Other	17,964	18,325
Total other liabilities	$ 85,071	$ 87,812

Income Tax Expense Income Tax E

Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate, Continuing Operations	14.70%	15.40%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%
Uncertain Tax Liability Resulting From IRS Notice	$ 25,000

Contingencies Leases (Details)

Contingencies Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Loss Contingencies [Line Items]
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 19,608
Operating Leases, Future Minimum Payments Due, Next Twelve Months		$ 24,008
Operating Leases, Future Minimum Payments Receivable, in Two Years		18,567
Operating Leases, Future Minimum Payments Receivable, in Three Years		13,917
Operating Leases, Future Minimum Payments Receivable, in Four Years		11,929
Operating Leases, Future Minimum Payments, Due Thereafter		93,939
Operating Leases, Future Minimum Payments Due		162,360
Lessor, Operating Lease, Payments to be Received, Five Years	11,645
Fixed Operating Lease Expense	7,049
Capital Lease Obligations, Current	20,139	0
Capital Lease Obligations, Noncurrent	102,488	0
Operating Leases, Future Minimum Payments, Due in Two Years	20,882
Lessor, Operating Lease, Payments to be Received, Four Years	16,377
Lessor, Operating Lease, Payments to be Received, Five Years	13,920
Finance Lease, Liability, Payments, Due after Year Five	78,771
Lessee, Operating Lease, Liability, Payments, Due	161,203
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	38,576
Operating Lease, Liability	122,627
Operating Lease, Payments	6,880
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	8,506
Operating Lease, Right-of-Use Asset	122,521	$ 0
Variable Operating Lease Expense	1,014
Operating Lease, Payments	$ 8,063

Business Segment Information _2

Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2019	Jun. 30, 2018
Segment Reporting Information [Line Items]
Revenues		$ 696,803	$ 638,758
Segment operating income		110,088	94,424
Restructuring Charges	[1]	2,307	0
Amortization of acquired intangible assets	[2]	16,949	18,055
Acquisition and integration related charges	[3]	1,917	1,671
loss (gain) on fair value contingent consideration adjustments		0	(842)	[2]
Impact of TCJA	[4]	1,770	287
Net loss on divestiture of businesses	[2]	2,426	444
Amortization of inventory and property step-up to fair value	[2]	735	611
Healthcare Products
Segment Reporting Information [Line Items]
Revenues		309,787	292,010
Segment operating income		73,698	61,722
Restructuring Charges		30,713
Healthcare Specialty Services
Segment Reporting Information [Line Items]
Revenues		135,945	122,249
Segment operating income		16,817	12,954
Restructuring Charges		2,518
Life Sciences
Segment Reporting Information [Line Items]
Revenues		96,785	84,955
Segment operating income		33,039	29,865
Restructuring Charges		668
Applied Sterilization Technologies
Segment Reporting Information [Line Items]
Revenues		154,286	139,544
Segment operating income		68,035	56,151
Restructuring Charges		7,798
Corporate
Segment Reporting Information [Line Items]
Segment operating income		(55,397)	(46,042)
Segment operating income
Segment Reporting Information [Line Items]
Revenues		696,803	638,758
Segment operating income		136,192	114,650
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues		170,543	178,658
UNITED STATES
Segment Reporting Information [Line Items]
Revenues		511,152	447,540
UNITED KINGDOM
Segment Reporting Information [Line Items]
Revenues		15,108	12,560
Consumable revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		108,782	100,414
Consumable revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		44,029	40,221
Sales Revenue, Services, Net [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		85,809	84,100
Sales Revenue, Services, Net [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		25,987	25,620
Capital equipment revenues [Member] | Healthcare Products
Segment Reporting Information [Line Items]
Revenues		115,196	107,496
Capital equipment revenues [Member] | Life Sciences
Segment Reporting Information [Line Items]
Revenues		$ 26,769	$ 19,114
[1]	(4) For more information regarding our restructuring activities see Note 2 titled, "Restructuring".
[2]	For more information regarding our recent acquisitions and divestitures see Note 17 titled, "Business Acquisitions and Divestitures", as well as our Annual Report on Form 10-K for the year ended March 31, 2019 , dated May 30, 2019 .
[3]	Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.
[4]	(3)

Shares and Preferred Shares Ord

Shares and Preferred Shares Ordinary Shares (Details)	3 Months Ended
	Jun. 30, 2019$ / sharesshares	Jun. 30, 2018shares	May 03, 2019$ / shares	Mar. 31, 2019$ / shares	Mar. 31, 2019EUR (€)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	84,638,000	84,685,000
Dilutive effect of share equivalents	928,000	824,000
Weighted average shares outstanding and share equivalents - diluted	85,566,000	85,509,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Authorized	50,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001	$ 75
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.001
Deferred Ordinary Shares	25,000
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	122,000	141,000
Euro Member Countries, Euro
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Par Value (Euros) of Deferred Ordinary Shares | €					€ 1

Shares and Preferred Shares Pre

Shares and Preferred Shares Preferred Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018
Class of Stock [Line Items]
Preferred shares, par value	$ 0.001
Preferred Stock, Value, issued		$ 15	$ 15

Repurchases of Shares Repurchas

Repurchases of Shares Repurchases of Shares (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jul. 30, 2019	May 07, 2019	Aug. 09, 2016
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized				$ 70,367	$ 300,000
Shares repurchased during period, number	60,000
Aggregate value of shares repurchased pursuant to authorization	$ 8,612
Shares obtained in connection with share based compensation award programs	66,745	89,730
Payments for shares obtained in connection with share based compensation programs	$ 7,446	$ 7,753
Share Repurchase Program [Domain]
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized			$ 300,000

Share-Based Compensation Shar_2

Share-Based Compensation Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	3,931,008
Weighted-average assumptions used for options granted:
Risk-free interest rate	2.27%	2.62%
Expected life of options	6 years 2 months 12 days	6 years 2 months 12 days
Exptected dividend yield of stock	1.23%	1.48%
Expected volatility of stock	20.27%	19.83%
Estimated forfeiture rate	2.77%	2.37%
Summary of share option activity:
Outstanding at March 31, 2017	2,104,685
Granted	334,236
Exercised	(217,543)
Forfeited	(667)
Outstanding at June 30, 2017	2,220,711
Exercisable at June 30, 2017	1,304,982
Weighted average exercise price:
Outstanding at March 31, 2017	$ 72.82
Granted	147.05
Exercised	49.45
Forfeited	72.57
Outstanding at June 30, 2017	86.28
Exercisable at June 30, 2017	$ 66.33
Average Remaining Contractual Term, Outstanding at June 30, 2017	7 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding at June 30, 2017	$ 139,012
Average Remaining Contractual Term, Exercisable at June 30, 2017	6 years
Aggregate Intrinsic Value, Exercisable at June 30, 2017	$ 107,729
Non-vested stock options outstanding expected to vest	880,401
Ordinary shares, closing price	$ 148.88
Total intrinsic value of stock options exercised	$ 18,843	$ 4,582
Net cash proceeds from the exercise of stock options	$ 9,899	$ 3,435
Weighted average grant date fair value of stock option grants, per share	$ 23.19	$ 17.53
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 58,089
Weighted Average Period For Total Compensation Expense Not Yet Recognized	2 years 5 months 4 days
Stock Appreciation Rights (SARs) [Member]
Weighted average exercise price:
FairValueOfOutstandingStockAppreciationRights	$ 610	$ 1,089
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	676,373
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 80.86
Number of Restricted Shares, Granted	138,460
Weighted-Average Grant Date Fair Value, Granted	$ 133.68
Number of Restricted Shares, Vested	(161,652)
Weighted-Average Grant Date Fair Value, Vested	$ 71.63
Number of Restricted Shares, Canceled	(8,717)
Weighted-Average Grant Date Fair Value, Canceled	$ 83.89
Number of Restricted Shares, Non-vested at End of Period	644,464
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 94.48
Fair Value, Share-based Payment Awards, Other than Options	$ 12,134
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	33,219
Number of Restricted Shares, Granted	6,540
Number of Restricted Shares, Vested	(7,746)
Number of Restricted Shares, Canceled	(554)
Number of Restricted Shares, Non-vested at End of Period	31,459

Financial and Other Guarantee_2

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2019USD ($)
Product Warranty Liability [Line Items]
Balance, March 31, 2017	$ 7,194
Warranties issued during the period	2,496
Settlement made during the period	(2,784)
Balance, June 30, 2017	$ 6,906

Derivatives and Hedging Fair Va

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, $ in Millions, $ in Millions	3 Months Ended
	Jun. 30, 2019MXN ($)lb	Jun. 30, 2019USD ($)	Jun. 30, 2019CAD ($)	Jun. 30, 2019EUR (€)	Mar. 31, 2019USD ($)
Derivative [Line Items]
Non-derivative Net Investment Hedge		$ 47,800
Prepaid & Other
Derivative [Line Items]
Asset derivatives		597			$ 552
Liability derivatives		0			0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives		0			0
Liability derivatives		$ 174			$ 278
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight | lb	506,000
Mexican peso | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount	$ 194.9
Canadian dollar | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount			$ 16.8
euro | Foreign currency forward contracts
Derivative [Line Items]
Derivative, notional amount | €				€ 10.8

Derivatives and Hedging Gain (L

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (406)	$ 358
Commodity swap contracts | Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (127)	$ 364

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt and Equity Securities, Gain (Loss)		$ 1,758	$ 1,377
Assets:
Investment Owned, at Cost			$ 4,955
Liabilities:
Contingent consideration obligations		5,991		$ 5,950
Level 1
Assets:
Cash and cash equivalents		238,067		220,633
Forward and swap contracts	[1]	0		0
Equity Securities, FV-NI	[2]	11,980		13,873
Investments		2,579		2,545
Liabilities:
Forward and swap contracts	[1]	0		0
Deferred compensation plans	[2]	1,598		1,564
Long term debt	[3]	0		0
Contingent consideration obligations	[4]	0		0
Level 2
Assets:
Cash and cash equivalents		0		0
Forward and swap contracts	[1]	597		552
Equity Securities, FV-NI	[2]	0
Investments		0		0
Liabilities:
Forward and swap contracts	[1]	174		278
Deferred compensation plans	[2]	0		0
Long term debt	[3]	1,250,848		1,200,558
Contingent consideration obligations	[4]	0		0
Level 3
Assets:
Cash and cash equivalents		0		0
Forward and swap contracts	[1]	0		0
Investments				0
Liabilities:
Forward and swap contracts	[1]	0		0
Deferred compensation plans	[2]	0		0
Long term debt	[3]	0		0
Contingent consideration obligations	[4]	5,991		5,950
Carrying Value
Assets:
Cash and cash equivalents		238,067		220,633
Forward and swap contracts	[1]	597		552
Equity Securities, FV-NI	[2]	11,980		13,873
Investments		2,579		2,545
Liabilities:
Forward and swap contracts	[1]	174		278
Deferred compensation plans	[2]	1,598		1,564
Long term debt	[3]	1,210,003		1,183,227
Contingent consideration obligations	[4]	$ 5,991		$ 5,950
[1]	(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[2]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2020 and 2019, we recorded losses of $1,758 and $1,377 , respectively, related to these investments.
[3]	We estimate the fair value of our long-term debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements.
[4]	Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Fair Value Measurements Conting

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2019	Mar. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration		$ 5,991	$ 5,950
Additions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		45
Foreign currency translation adjustment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration		(4)
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	[1]	$ 5,991	5,950
Fair value			$ 0
[1]	Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Fair Value Measurements Availab

Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Debt Securities, Available-for-sale [Line Items]
Equity Securities, FV-NI, Gain (Loss)	$ (1,758)	$ (1,377)

Reclassifications out of Accu_3

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2019		Jun. 30, 2018		Mar. 31, 2019		Mar. 31, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (156,844)		$ (121,096)		$ (159,778)		$ 11,685
Other Comprehensive Income (Loss), Net of Tax		3,629		(130,248)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		695		563
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent		(2,934)		130,811
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification				(5,637)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax				0				1,970
Other Comprehensive (Loss) Income, Available-for-sale Securities Adjustment, Net of Tax				0
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax				0
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent				0
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax		4,709	[1]	7,152	[2]	4,204	[1]	6,742	[2]
Other Comprehensive Income (Loss), Net of Tax		(190)	[1]	(153)	[2]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		695	[1]	563	[2]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent		505	[1]	410	[2]
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	[3]	(152,135)		(113,944)		$ (155,574)		$ 16,457
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	[3]	3,439		(130,401)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[3]	0		0
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent	[3]	$ (3,439)		130,401
Including Impact of Adoption of ASU 2016-01 [Domain]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent				130,811
Accounting Standards Update 2016-01 [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	[4]			$ (1,970)
[1]	nts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accu
[2]	Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.
[3]	The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
[4]	As a result of the adoption of ASC 2016-01, we recorded a cumulative effect adjustment to our opening fiscal 2019 retained earnings balance that increased retained earnings and decreased accumulated other comprehensive income.

Loans Receivable (Details)

Loans Receivable (Details) € in Thousands, $ in Thousands	Jun. 30, 2019USD ($)	Jun. 30, 2019EUR (€)	Mar. 31, 2019USD ($)	Mar. 31, 2019EUR (€)	Jun. 30, 2018USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investments					$ 4,955
Line of Credit Provide					$ 10,000
Equity Investee Loan [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing Receivable, after Allowance for Credit Loss	$ 7,638		$ 7,465
Dutch Linen Loan [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Financing Receivable, after Allowance for Credit Loss	$ 8,606	€ 7,567	$ 8,494	€ 7,550
Loan Agreement Max Borrowing Amount Dutch Linen Sale | €		€ 15,000
Years 1-4, 4% Int Rate [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.00%	4.00%
Loan Rate 4% [Member] [Domain]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					4.00%
Years 5-15, 12% Int Rate [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%	12.00%

Restructuring (Details)

Restructuring (Details) $ in Thousands		3 Months Ended
		Jun. 30, 2019USD ($)plan	Jun. 30, 2018USD ($)	Mar. 31, 2019USD ($)
Restructuring and Related Cost, Expected Number of Positions Eliminated | plan		200
Restructuring expense incurred since Plan inception		$ 43,015
Restructuring Reserve		5,365		$ 6,131
Restructuring Costs		1,389	$ 0
Restructuring Charges	[1]	2,307	$ 0
Restructuring Reserve, Accrual Adjustment		1,093
Increase (Decrease) in Restructuring Reserve	[2]	(1,859)
Operating Expense [Member]
Restructuring Charges		32,376
Cost of Goods and Service Benchmark [Member]
Restructuring Charges		10,639
Product Rationalization [Member]
Restructuring Costs	[3]	918
Employee Severance [Member]
Restructuring Reserve		3,623		4,102
Restructuring Costs		1,091
Restructuring Reserve, Accrual Adjustment		1,091
Increase (Decrease) in Restructuring Reserve	[2]	1,570
Contract Termination [Member]
Restructuring Reserve		1,742		$ 2,029
Restructuring Costs		298
Restructuring Reserve, Accrual Adjustment		2
Increase (Decrease) in Restructuring Reserve	[2]	289
Healthcare Products [Member] [Member]
Restructuring Charges		30,713
Healthcare Specialty Services [Member]
Restructuring Charges		2,518
Life Science Member [Member]
Restructuring Charges		668
Applied Sterilization Technologies [Member]
Restructuring Charges		7,798
Corporate, Non-Segment [Member]
Restructuring Charges		$ 1,318
[1]	(4) For more information regarding our restructuring activities see Note 2 titled, "Restructuring".
[2]	Certain amounts reported include the impact of foreign currency movements relative to the U.S. dollar.
[3]	Recorded in cost of revenues on the Consolidated Statements of Income.